BRD4 and cancer: In 2021, Liu et al. developed a cancer-selectivePROTAC on thebasis of reported BRD4 PROTAC ARV-771.61 The folate-PROTAC 10 (Table 1, entry 10) designed by incorporating folatevia an ester bond onto the hydroxyl group of ARV-771, demonstratedcomparable BRD4 degradation in cancer cells versus noncancerous normalcells with the parental compound ARV-771.